semaglutide
5 Obesity Treatment Wins From GLP‑1 That Cut Alcohol
In a 15-week pilot, semaglutide cut heavy drinking days by 35% and nudged BMI down 3.1 points, with no serious adverse events reported. The study enrolled adults with obesity who also struggled with frequent binge drinking, showing that a single GLP-1 drug can address two hard-to-treat conditions at once.